

Protein kinase C phosphorylates DNA topoisomerase I

D. Scott Samuels⁺, Yoshiko Shimizu⁺ and Nobuyoshi Shimizu^{+o}

⁺*Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85721, USA* and ^o*Department of Molecular Biology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160, Japan*

Received 23 October 1989

The induction of mammalian cell proliferation requires the expression of a specific set of genes. Tumor promoters stimulate cell growth by activating the Ca²⁺ and phospholipid-dependent protein kinase, protein kinase C (PKC). DNA topoisomerase I, a nuclear enzyme involved in transcription, was phosphorylated by activated PKC *in vitro*. Phosphorylation by PKC stimulated the DNA relaxation activity of topoisomerase I two- to three-fold. Therefore, DNA topoisomerase I is a substrate for PKC-mediated activation by phosphorylation and may serve as a nuclear target of mitogenic signals generated by tumor promoters *in vivo*.

Protein kinase C; Topoisomerase I, DNA-; Protein phosphorylation; Mitogenic signal transduction; Nuclear target

1. INTRODUCTION

The tumor-promoting phorbol ester TPA, and other mitogens, induce the expression of a set of genes involved in cellular growth and transformation. PKC, the serine and threonine-specific, Ca²⁺- and phospholipid-dependent, diacylglycerol-activated kinase, is the major receptor for TPA and is stimulated by treatment with ligands that induce the turnover of inositol phospholipids [1-3]. PKC is thought to regulate numerous metabolic events in the cell, including transmembrane signal transduction, gene expression and cell growth [3,4].

Topoisomerase I transiently nicks a single DNA strand, catalyzing topological manipulations such as the relaxation of supercoiled DNA molecules [5-7]. DNA topoisomerase I is required for rRNA synthesis [8-10] and is associated with transcriptionally active genes [11-19], where it is probably involved in resolving local supercoiling caused by the transcriptional machinery [20-23]. The activity of topoisomerase I increases during cell proliferation [24-26].

Several *in vitro* substrates for PKC have been identified, including the nuclear enzymes DNA topoisomerase II [27,28], DNA methyltransferase [29], DNA polymerase α [30] and RNA polymerase II [31] as well as the nuclear factor CREB [32]. We report here

that PKC also phosphorylates DNA topoisomerase I *in vitro* resulting in a two- to three-fold increase in topoisomerase I activity and suggest a role for nuclear PKC in the signal transduction pathway for the induction of cell proliferation.

2. MATERIALS AND METHODS

2.1. Enzymes

Topoisomerase I was purified to near homogeneity from HeLa cells essentially as described previously [7]. PKC was purified from mouse brain using DE52 DEAE-cellulose (Whatman) and FPLC Mono Q (Pharmacia) column chromatography as described previously [33], except chromatography in the presence of ATP was not performed and the column buffers contained 0.1% Triton X-100.

2.2. Phosphorylation reaction

Reactions contained 20 mM Tris-HCl, pH 7.5, 1 mM MgCl₂, 0.5 μ g/ml leupeptin, 2 μ g/ml aprotinin, 0.7 μ g/ml pepstatin A, 1 mM PMSF, 0.5 mM Na₃VO₄, 10 mM *p*-nitrophenyl phosphate, and either 0.1 mM CaCl₂, 25 μ g/ml PS and 100 ng/ml TPA or 2 mM EGTA, in 30 μ l. Reactions were either in the presence or absence of 0.016 units PKC (90 units/mg) and 25 ng topoisomerase I. One unit was defined as the amount of PKC required to transfer 1 nmol of ³²P, from [γ -³²P]ATP to histone (calf thymus, type III-S, Sigma) in 15 min at 30°C. The reaction was initiated by adding 0.1 μ M [γ -³²P]-ATP (22 μ Ci; ICN), incubated at 30°C for 15 min, and terminated by placing in an ice-water bath, adding 30 μ l 2 \times Laemmli's sample loading buffer [34] and heating in a boiling water bath for 5 min. Samples were electrophoresed on a 7% SDS-polyacrylamide gel for 14 h at 70 V (4.6 V/cm). Gels were fixed, dried and exposed to Konica type A film with intensifying screens at -70°C for 1 day.

2.3. Immunoprecipitation

The phosphorylation reaction (30 μ l) was terminated by placing in an ice-water bath and adding 2 μ l 0.1 M EGTA, pH 7.5, and was then diluted with 1 ml 10 mM sodium phosphate, pH 7.5, 150 mM NaCl, 0.5% Triton X-100, 1 mM EDTA, 0.5 mM Na₃VO₄, and 1 mM PMSF. This was added to 20 μ l Protein A-Sepharose CL-4B (Pharmacia) loaded with 6 μ g anti-topoisomerase antibody [35] and incubated with gentle agitation at 4°C for 16 h. The supernatant (flow-

Correspondence address: N. Shimizu, Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85721, USA

Abbreviations: PKC, protein kinase C; TPA, 12-*O*-tetradecanoyl-phorbol-13-acetate; FPLC, fast protein liquid chromatography; PMSF, phenylmethylsulfonyl fluoride; PS, phosphatidylserine; EGTA, [ethylenebis(oxyethylenitrilo)]tetraacetic acid; SDS, sodium dodecyl sulfate; TCA, trichloroacetic acid

through) was collected by acid precipitation with 20% TCA and resuspended in 30 μ l buffer A. The pellet (immunoprecipitate) was washed essentially as described previously [36] and resuspended in 30 μ l 2 \times Laemmli's sample loading buffer [34]. Electrophoresis was performed as described above.

2.4. Topoisomerase I assay

Topoisomerase I was phosphorylated by PKC essentially as described above, except the reaction was terminated by placing in an ice-water bath and adding 1.5 μ l 0.1 M EGTA, pH 7.5. Reactions were diluted in 6% polyethylene glycol 8000, 20 mM Tris-HCl, pH 7.5, 1 mM 2-mercaptoethanol, and 10 μ g/ml bovine serum albumin. DNA relaxation activity was measured essentially as previously described [7,35]; the reaction was initiated by addition of diluted phosphorylation reaction (0.5 to 2.5 ng topoisomerase I).

3. RESULTS

Human DNA topoisomerase I was incubated with murine PKC *in vitro* to determine if phosphorylation mediated by PKC modulates topoisomerase I activity. Topoisomerase I was purified as a single polypeptide with a molecular mass of 100 000 Da (data not shown). PKC, a heterogeneous family of proteins with an average molecular mass of 77 000 Da, was activated by Ca^{2+} , PS and TPA resulting in its autophosphorylation (fig.1, lane 2). The phosphorylation of PKC in the absence of the activators Ca^{2+} , PS and TPA was less than 10% of the phosphorylation in their presence (fig.1, lane 1).

The topoisomerase I preparation contained no autophosphorylating activity in the presence or absence of Ca^{2+} , PS and TPA (fig.1, lanes 3,4). However, topoisomerase I was significantly phosphorylated by activated PKC *in vitro* (fig.1, lane 6). The identity of the phosphorylated protein was confirmed by immunoprecipitation from the PKC reaction with an anti-topoisomerase I antiserum [35] (fig.2). The possibility that one of the ten other phosphoproteins in the PKC fraction is a kinase that is activated by PKC and phosphorylates topoisomerase I was eliminated by phosphorylation of topoisomerase I by three distinct PKC subspecies isolated by fractionating the protein kinase preparation on hydroxyapatite column chromatography (Samuels, D.S. and Shimizu, N., manuscript in preparation).

Phosphorylation of DNA topoisomerase I by PKC resulted in a two- to three-fold increase in topoisomerase I activity as assayed by the conversion of supercoiled form I DNA molecules to their relaxed topoisomers. The relaxed form I topoisomers migrated slower than the supercoiled molecules during agarose gel electrophoresis due to their decreased compactness. The effect of PKC-mediated phosphorylation was tested after preincubation of topoisomerase I in the absence or presence of PKC in the phosphorylation reaction.

Approximately 1.4 ng of untreated topoisomerase I relaxed half of the supercoiled plasmid while less than 0.7 ng of topoisomerase I phosphorylated by PKC was




Fig.1. Phosphorylation of DNA topoisomerase I by PKC. Reactions contained either $CaCl_2$, PS and TPA (lanes 2,4,6) or EGTA (lanes 1,3,5) and were in the presence (lanes 1,2,5,6) or absence (lanes 3,4) of PKC and the presence (lanes 3-6) or absence (lanes 1,2) of DNA topoisomerase I (Topo I).




Fig.2. Immunoprecipitation of phosphorylated DNA topoisomerase I. Immunoprecipitate using anti-DNA topoisomerase I antibody (lane 1) and flow-through (lane 2) from the PKC phosphorylation reaction with DNA topoisomerase I (Topo I).




Fig.3. Relaxation activity of phosphorylated DNA topoisomerase I. Reactions contained DNA topoisomerase I (0.5 to 2.5 ng) preincubated in the phosphorylation reaction without PKC (Topo I) or with PKC (Topo I- PO_4^{3-}). DNA topoisomerase I converted supercoiled form I plasmid DNA (I) to relaxed form I plasmid DNA which migrated through agarose gel electrophoresis at the same position as form II plasmid DNA (II).

required to relax the same amount of DNA (fig.3). This trend persisted at other dilutions indicating that inhibition of untreated topoisomerase I by ATP not expended in the reaction or PS and TPA not bound to PKC did not significantly contribute to the difference in activity of topoisomerase I preincubated with and without PKC. PKC had no intrinsic topoisomerase I activity (data not shown).

4. DISCUSSION

Topoisomerase I is most likely regulated in vivo by phosphorylation [37,38]. Its activity [24–26], but not the amount or stability of the protein [39], varies during the cell cycle. Topoisomerase I is isolated from Novikoff hepatoma cells and *Xenopus laevis* ovaries as a phosphoprotein and treatment of it with alkaline phosphatase decreases or abolishes its DNA relaxation activity [38,40]. In addition, it is phosphorylated by casein kinase II in vitro resulting in the stimulation of its activity approximately three-fold [38,40,41].

DNA topoisomerase I is a nuclear enzyme; PKC has also been detected in the nucleus [42–52]. Preliminary results indicate that a topoisomerase I-like phosphoprotein is present in the nucleus of mouse fibroblasts from 10 to 75 min after TPA treatment (Samuels, D.S. and Shimizu, N., unpublished results), shortly after the appearance of activated PKC in the nucleus [42,45,46,49,52–59], when early genes required for DNA synthesis, such as *c-fos* and *c-myc*, are expressed.

Topoisomerase I is likely to be a physiologically important substrate for PKC because of its role in transcription and the effect phosphorylation has on its DNA relaxation activity. This post-translational regulation may be a key event in the induction of gene expression by tumor promoters. Several other nuclear proteins are also substrates for PKC in vitro [27–32]. Histones H2B, H4 and H1^o [53,55], nuclear matrix proteins NP80 and NP33 [54], lamin B [56,57] as well as the nuclear proteins encoded by *c-erbA* [58] and *ets-2* [59]

are phosphorylated in response to TPA treatment in vivo. Thus, PKC could prove to be an essential kinase in the control of nuclear processes during, and in preparation for, cell growth and differentiation.

Acknowledgements: This work was supported by a Public Health Service grant from the National Institutes of Health (GM-24375) and a predoctoral training award sponsored by a National Research Service Award from the National Cancer Institute (CA-09213). We thank Dr Grace Pavlath for critical reading of the manuscript and Dr Samuel Ward for technical advice on immunoprecipitation.

REFERENCES

- [1] Nishizuka, Y. (1984) *Nature* 308, 693–698.
- [2] Kuo, J.F., Schatzman, R.C., Turner, R.S. and Mazzei, G.J. (1984) *Mol. Cell. Endocrinol.* 35, 65–73.
- [3] Nishizuka, Y. (1986) *Science* 233, 305–312.
- [4] Kikkawa, U. and Nishizuka, Y. (1986) *Annu. Rev. Cell Biol.* 2, 149–178.
- [5] Vosberg, H.-P. (1985) *Curr. Top. Microbiol. Immunol.* 114, 19–102.
- [6] Wang, J.C. (1985) *Annu. Rev. Biochem.* 54, 665–697.
- [7] Liu, L.F. and Miller, K.G. (1981) *Proc. Natl. Acad. Sci. USA* 78, 3487–3491.
- [8] Garg, L.C., DiAngelo, S. and Jacob, S.T. (1987) *Proc. Natl. Acad. Sci. USA* 84, 3185–3188.
- [9] Zhang, H., Wang, J.C. and Liu, L.F. (1988) *Proc. Natl. Acad. Sci. USA* 85, 1060–1064.
- [10] Rose, K.M., Szopa, J., Han, F.-S., Cheng, Y.-C., Richter, A. and Scheer, U. (1988) *Chromosoma* 96, 411–416.
- [11] Fleischmann, G., Pflugfelder, G., Steiner, E.K., Javaherian, K., Howard, G.C., Wang, J.C. and Elgin, S.C.R. (1984) *Proc. Natl. Acad. Sci. USA* 81, 6958–6962.
- [12] Bonven, B.J., Gocke, E. and Westergaard, O. (1985) *Cell* 41, 541–551.
- [13] Muller, M.T., Pfund, W.P., Mehta, V.B. and Trask, D.K. (1985) *EMBO J.* 4, 1237–1243.
- [14] Gilmour, D.S., Pflugfelder, G., Wang, J.C. and Lis, J.T. (1986) *Cell* 44, 401–407.
- [15] Gilmour, D.S. and Elgin, S.C.R. (1987) *Mol. Cell. Biol.* 7, 141–148.
- [16] Stewart, A.F. and Schütz, G. (1987) *Cell* 50, 1109–1117.
- [17] Muscarella, D.E., Vogt, V.M. and Bloom, S.E. (1987) *J. Cell Biol.* 105, 1501–1513.
- [18] Culotta, V. and Sollner-Webb, B. (1988) *Cell* 52, 585–597.
- [19] Ness, P.J., Koller, T. and Thoma, F. (1988) *J. Mol. Biol.* 200, 127–139.
- [20] Osborne, B.I. and Guarente, L. (1988) *Genes Dev.* 2, 766–772.
- [21] Brill, S.J. and Sternglanz, R. (1988) *Cell* 54, 403–411.
- [22] Giaever, G.N. and Wang, J.C. (1988) *Cell* 55, 849–856.
- [23] Tsao, Y.-P., Wu, H.-Y. and Liu, L.F. (1989) *Cell* 56, 111–118.
- [24] Poccia, D.L., LeVine, D. and Wang, J.C. (1978) *Dev. Biol.* 64, 273–283.
- [25] Tricoli, J.V., Sahai, B.M., McCormick, P.J., Jarlinski, S.J., Bertram, J.S. and Kowalski, D. (1985) *Exp. Cell Res.* 158, 1–14.
- [26] Kafiani, C.A., Bronstein, I.B., Timofeev, A.V., Gromova, I.I. and Terskikh, V.V. (1986) *Adv. Enzyme Regul.* 25, 439–457.
- [27] Sahyoun, N., Wolf, M., Besterman, J., Hsieh, T.-S., Sander, M., LeVine iii, H., Chang, K.-J. and Cuatrecasas, P. (1986) *Proc. Natl. Acad. Sci. USA* 83, 1603–1607.
- [28] Rottmann, M., Schröder, H.C., Gramzow, M., Renneisen, K., Kurelec, B., Dorn, A., Friese, U. and Müller, W.E.G. (1987) *EMBO J.* 6, 3939–3944.
- [29] DePaoli-Roach, A., Roach, P.J., Zucker, K.E. and Smith, S.S. (1986) *FEBS Lett.* 197, 149–153.

- [30] Krauss, S.W., Mochly-Rosen, D., Koshland jr., D.E. and Linn, S. (1987) *J. Biol. Chem.* 262, 3432-3435.
- [31] Chuang, L.F., Cooper, R.H., Yau, P., Bradbury, E.M. and Chuang, R.Y. (1987) *Biochem. Biophys. Res. Commun.* 145, 1376-1383.
- [32] Yamamoto, K.K., Gonzalez, G.A., Biggs iii, W.H. and Montminy, M.R. (1988) *Nature* 334, 494-498.
- [33] Jeng, A.Y., Sharkey, N.A. and Blumberg, P.M. (1986) *Cancer Res.* 46, 1966-1971.
- [34] Laemmli, U.K. (1970) *Nature* 227, 680-685.
- [35] Samuels, D.S., Tojo, T., Homma, M. and Shimizu, N. (1986) *FEBS Lett.* 209, 231-234.
- [36] Fambrough, D.M. and Bayne, E.K. (1983) *J. Biol. Chem.* 258, 3926-3935.
- [37] Durban, E., Goodenough, M., Mills, J. and Busch, H. (1985) *EMBO J.* 4, 2921-2926.
- [38] Kaiserman, H.B., Ingebritsen, T.S. and Benbow, R.M. (1988) *Biochemistry* 27, 3216-3222.
- [39] Heck, M.M.S., Hittelman, W.N. and Earnshaw, W.C. (1988) *Proc. Natl. Acad. Sci. USA* 85, 1086-1090.
- [40] Durban, E., Mills, J.S., Roll, D. and Busch, H. (1983) *Biochem. Biophys. Res. Commun.* 111, 897-905.
- [41] Mills, J.S., Busch, H. and Durban, E. (1982) *Biochem. Biophys. Res. Commun.* 109, 1222-1227.
- [42] Shimizu, Y. and Shimizu, N. (1989) *Somat. Cell Mol. Genet.* 15, 321-329.
- [43] Wood, J.G., Girard, P.R., Mazzei, G.J. and Kuo, J.F. (1986) *J. Neurosci.* 6, 2571-2577.
- [44] Capitani, S., Girard, P.R., Mazzei, G.J., Kuo, J.F., Berezney, R. and Manzoli, F.A. (1987) *Biochem. Biophys. Res. Commun.* 142, 367-375.
- [45] Cambier, J.C., Newell, M.K., Justement, L.B., McGuire, J.C., Leach, K.L. and Chen, Z.Z. (1987) *Nature* 327, 629-632.
- [46] Thomas, T.P., Talwar, H.S. and Anderson, W.B. (1988) *Cancer Res.* 48, 1910-1919.
- [47] Kiss, Z., Deli, E. and Kuo, J.F. (1988) *FEBS Lett.* 231, 41-46.
- [48] Kose, A., Saito, N., Ito, H., Kikkawa, U., Nishizuka, Y. and Tanaka, C. (1988) *J. Neurosci.* 8, 4262-4268.
- [49] Buckley, A.R., Crowe, P.D. and Russell, D.H. (1988) *Proc. Natl. Acad. Sci. USA* 85, 8649-8653.
- [50] Huang, F.L., Yoshida, Y., Nakabayashi, H., Young iii, W.S. and Huang, K.-P. (1988) *J. Neurosci.* 8, 4734-4744.
- [51] Masmoudi, A., Labourdette, G., Mersel, M., Huang, F.L., Huang, K.-P., Vincendon, G. and Malviya, A.N. (1989) *J. Biol. Chem.* 264, 1172-1179.
- [52] Leach, K.L., Powers, E.A., Ruff, V.A., Jaken, S. and Kaufmann, S. (1989) *J. Cell Biol.* 109, 685-695.
- [53] Patskan, G.J. and Baxter, C.S. (1985) *J. Biol. Chem.* 260, 12899-12903.
- [54] Macfarlane, D.E. (1986) *J. Biol. Chem.* 261, 6947-6953.
- [55] Butler, A.P., Byus, C.V. and Slaga, T.J. (1986) *J. Biol. Chem.* 261, 9421-9425.
- [56] Hornbeck, P., Huang, K.-P. and Paul, W.E. (1988) *Proc. Natl. Acad. Sci. USA* 85, 2279-2283.
- [57] Fields, A.P., Pettit, G.R. and May, S.W. (1988) *J. Biol. Chem.* 263, 8253-8260.
- [58] Goldberg, Y., Glineur, C., Gesquière, J.-C., Ricouart, A., Sap, J., Vennström, B. and Ghysdael, J. (1988) *EMBO J.* 7, 2425-2433.
- [59] Fujiwara, S., Fisher, R.J., Bhat, N.K., Diaz de la Espina, S.M. and Papas, T.S. (1988) *Mol. Cell. Biol.* 8, 4700-4706.